Here are five things to know.
1. Mr. Mahjoubi will step into his new role Dec. 30.
2. He will replace Herve Brailly, who is set to become chairman of the company’s advisory board.
3. Mr. Mahjoubi will be paid a base salary of 470,000 euros ($490,000) and also receive free shares in the company, according to the report.
4. Before joining AstraZeneca, Mr. Mahjoubi worked at Roche’s Genentech unit, where he helped lead oncology strategy.
5. The British drugmaker said Mr. Mahjoubi’s successor would be announced shortly, according to the report.
More articles on supply chain:
Amazon looking to develop ‘Uber’ for truck shipments
5 supply chain strategies to control hospital drug spending
FDA removes mental health warning from Pfizer’s anti-smoking drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
